2013 AACR: Evaluation oral bioavailability and intermittent dosing schedule for PD effects by SGI-11

/in , ,

2013 AACR: Evaluation oral bioavailability and intermittent dosing schedule for PD effects by SGI-11

2013 TAT: IMMUNOMODULATORY ACTIVITY OF SGI-110, A SECOND GENERATION HYPOMETHYLATING AGENT

/in , ,

2013 TAT: IMMUNOMODULATORY ACTIVITY OF SGI-110, A SECOND GENERATION HYPOMETHYLATING AGENT

2013: IASLC WCLC AT13387 Displays Single Agent Activity in Erlotinib-Sensitive & -Resistant NSCLC

/in , ,

2013: IASLC WCLC AT13387 Displays Single Agent Activity in Erlotinib-Sensitive & -Resistant NSCLC

2013 EORTC: Potent Dual cIAP1/XIAP Antagonists Induce Apoptosis in Melanoma Stem Cell Population

/in , ,

2013 EORTC: Potent Dual cIAP1/XIAP Antagonists Induce Apoptosis in Melanoma Stem Cell Population

2013 GI Conference: AT13387, A Novel Non-Ansamycin Inhibitor of HSP 90 is Active against GIST

/in , ,

2013 GI Conference: AT13387, A Novel Non-Ansamycin Inhibitor of HSP 90 is Active against GIST

2013 AACR: AT-IAP, a dual cIAP1 and XIAP antagonist with oral antitumor activity in melanoma models

/in , ,

2013 AACR: AT-IAP, a dual cIAP1 and XIAP antagonist with oral antitumor activity in melanoma models

2012 EORTC: Activity of the HSP90 inhibitor AT13387 in ALK-driven tumor models

/in , ,

2012 EORTC: Activity of the HSP90 inhibitor AT13387 in ALK-driven tumor models

2012 Apoptosis and Cancer: A Potent XIAP And cIAP1 Dual Antagonist Is Effective In Melanoma Models

/in , ,

2012 Apoptosis and Cancer: A Potent XIAP And cIAP1 Dual Antagonist Is Effective In Melanoma Models

2012 EORTC: SGI-110 enhances sorafenib activity and alters methylation signature of HCC Cell lines

/in , ,

2012 EORTC: SGI-110 enhances sorafenib activity and alters methylation signature of HCC Cell lines